Financial assistance is gratefully acknowledged from:
Click on a sponsor to learn more
Click on a sponsor to learn more
MCI Group collects your personal data to submit information related to EAHAD. For more information:
Privacy Statement.
© 16th Annual Congress of the European
Association for Haemophilia and Allied Disorders 2023
Bayer is a global enterprise with core competencies in the Life Science fields of health care and nutrition. Its products and services are designed to benefit people and improve their quality of life. We are driven by helping people with hemophilia thrive. Over the past 30 years, we have developed a deep understanding of the evolving aspirations of people with hemophilia. Bayer’s portfolio of rFVIII treatments offer hemophilia A patients a treatment to suit their individual needs and lifestyles.
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. Our parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people, and delivers its lifesaving therapies to people in more than 100 countries. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSLBehring.
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
The International Society on Thrombosis and Haemostasis (ISTH) is a global not-for-profit membership organization advancing the understanding, prevention, diagnosis and treatment of thrombotic and bleeding disorders. The Society is dedicated to transformative scientific discoveries and clinical practices, the development of young professionals and the education of physicians, scientists and allied health professionals wherever they may live.
Since 1999, The France Foundation (TFF) has been at the forefront of planning, developing, and implementing certified medical education. In support of improving patient care, TFF is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. TFF has implemented thousands of educational activities for over 20 years. They have collaborated with more than 30 academic medical centers, professional associations and medical societies throughout North America and Europe and are always seeking additional opportunities to break new ground.
LFB is a biopharmaceutical group that develops, manufactures and markets plasma-derived medicinal products and recombinant proteins for the treatment of patients with serious and often rare diseases.
Created in France in 1994, LFB is today one of the leading European companies providing plasma-derived medicinal products to healthcare professionals. Its mission is to offer patients new treatment options in three major therapeutic areas: immunology, haemostasis and intensive care.
LFB currently markets 15 medicinal products in about 30 countries.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.
www.novonordisk.com
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, with a combined capacity of approximately 8 million litres of plasma per annum. In addition, Octapharma operates more than 180 plasma donation centres across Europe and the US.
Octapharma employs around 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas:
For more information visit our website.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. In the UK, Pfizer has its business headquarters in Surrey and is a major supplier of medicines to the NHS.
To learn more about our commitments, please visit us at www.pfizer.co.uk or follow us on Twitter (@Pfizer_UK), Facebook (@PfizerUK) and Instagram (@pfizeruk).
PP-UNP-GBR-1982| September 2022
Within haemophilia Sobi is dedicated to the treatment of rare and severe diseases. This dedication combined with a rare expertise has resulted in a long history of developing transformative treatments for patients with high unmet medical needs. Our ability to identify unmet medical needs, develop treatments and secure evidence has been instrumental in the success of our current therapies. Our track record in getting innovative treatments to the people who need them positions us well to take a leading role in haemophilia. We keep challenging the status quo and are dedicated to the continuous discovery of high-potential therapies that we can develop to make a lasting impact and create sustainable value, sooner rather than later. Through close collaboration with rare disease communities, we continue to improve access to care for those otherwise overlooked.
You can find more information about Sobi at www.sobi.com.
At Spark Therapeutics, we are leveraging our unique technical and R&D expertise as we strive to bring gene therapies to patients. One of our areas of research is haemophilia A, an inherited bleeding disorder caused by mutations in the F8 gene that encodes coagulation factor VIII. Led by researchers and clinicians with long-standing commitment to the haemophilia community, we recognize the essential need to understand and gain important perspectives from patients, caregivers and leaders in the community. Spark Therapeutics is a member of the Roche Group.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI), with expertise in immune and inflammatory diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit your local Takeda website or speak to a member of the Takeda team.